Log In
Print
BCIQ
Print
Print this Print this
 

Oratecan

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionOral irinotecan plus P glycoprotein inhibitor (HM30181A; MDR1)
Molecular Target P glycoprotein (MDR1) (ABCB1) (P-gp) (CD243)
Mechanism of ActionP glycoprotein (MDR) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today